Stocktoria
CollPlant Biotechnologies Ltd CLGN
CollPlant Biotechnologies Ltd (CLGN) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $2.4M at a -484.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.42 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CLGN | CollPlant Biotechnologies Ltd | 3/9 | — | — | — |
| FEED | ENvue Medical, Inc. | 2/9 | -6.2 | — | — |
| NTRB | NutriBand Inc. | 3/9 | -15.84 | — | — |
| AVR | Anteris Technologies Global Corp. | 2/9 | — | — | — |
| SPAI | Safe Pro Group Inc. | 4/9 | 9.05 | — | — |
| COCH | Envoy Medical, Inc. | 2/9 | — | — | — |
| CUPR | Cuprina Holdings (Cayman) LTD | 4/9 | -2.57 | — | — |
About CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound care product for the treatment of deep surgical incisions and deep wounds. It also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. The company has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
FAQ
Is CLGN financially healthy?
CollPlant Biotechnologies Ltd's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does CLGN pay a dividend?
No, CollPlant Biotechnologies Ltd does not currently pay a dividend.
How profitable is CLGN?
In FY2025, CollPlant Biotechnologies Ltd had a net margin of -484.6% and a return on equity of -188.9%.
Is CLGN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on CollPlant Biotechnologies Ltd: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.